EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

SHPro ® (mixture of Angelica gigas and Astragalus membranaceus ) in men with lower urinary tract symptoms: A randomized, double-blind, placebo-controlled clinical trial

Ji Hun Lee iD, Dahye Yoon iD, Geum Duck Park iD, Kyung Seok Kim iD, Soo Ro Kim iD, Woo Cheol Shin iD, Seung Hwan Lee iD, Dae Young Lee iD

Investigative and Clinical Urology · 2025

DOI: 10.4111/icu.20250025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Investigative and Clinical Urology, 2025. Verfasst von Ji Hun Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Angelica, Astragalus propinquus, Prostatic Hyperplasia, Lower Urinary Tract Symptoms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: RDA, Rural Development Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: preclinical trial confirmed that Angelica gigas and Astragalus membranaceus had a curative effect on benign prostatic hyperplasia (BPH). Therefore, this study aimed to investigate the effects of this compound in patients with BPH symptoms. MATERIALS AND METHODS: Subjects were divided into the treatment and control groups. They underwent four visits, and medication was initiated from the 2nd visit onwards, with a total of 12 weeks of intake. The endpoints were the International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF), prostate-specific antigen level, testosterone, dihydrotestosterone, maximal urinary flow rate, residual urine volume, and subjective evaluation improvement. Safety tests included clinical pathology tests and checking for adverse reactions. RESULTS: A total of 39 patients from the treatment group and 45 from the control group were included in the efficacy analysis. After 12 weeks, a significant improvement was seen in IPSS total score (p=0.0219) and incomplete emptying score (p=0.0007). Furthermore, there were statistically significant improvements in the IIEF total score, erectile function, sexual desire, intercourse satisfaction, and overall satisfaction in the treatment group. The subjective improvement evaluation also showed a significant improvement (p=0.0143). Ten cases of mild adverse events were reported, including gastrointestinal problems, skeletal pain, dermatitis, and others. However, no severe adverse reactions were observed, and it was unlikely that these were related to the test product. CONCLUSIONS: After taking the trial product (SHPro®) for 12 weeks, the total and incomplete emptying IPSS improved, as did the IIEF, which indicated subjective improvements. And its safety was confirmed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AngelicaAstragalus propinquusProstatic HyperplasiaLower Urinary Tract SymptomsDrugs, Chinese HerbalPhytotherapyPlant ExtractsMaleHumansDouble-Blind MethodMiddle AgedAgedTreatment Outcome

Stichwörter der Autor:innen

Clinical trialDihydrotestosteronePharmacologic effectsSHPro®Safety

Substanzen

Drugs, Chinese HerbalPlant Extracts

Autor:innen und Institutionen

  • Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Herbal Crop Research, National Institute of Horticultural and Herbal Science, Rural Development Administration, Eumseong, Korea.
  • Suheung Technology Research Institute, Gwacheon, Korea.
  • BK21 FOUR KNU Creative BioResearch Group, School of Life Sciences, Kyungpook National University, Daegu, Korea.
  • Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. leeseh@yuhs.ac.
  • BK21 FOUR KNU Creative BioResearch Group, School of Life Sciences, Kyungpook National University, Daegu, Korea. dylee80@knu.ac.kr.

ORCID-Profile: Ji Hun Lee, Dahye Yoon, Geum Duck Park, Kyung Seok Kim, Soo Ro Kim, Woo Cheol Shin, Seung Hwan Lee, Dae Young Lee

Förderung

  • RDA
  • Rural Development Administration

Zitieren

APA

Lee, J. H., Yoon, D., Park, G. D., Kim, K. S., Kim, S. R., Shin, W. C., Lee, S. H., & Lee, D. Y. (2025). SHPro ® (mixture of Angelica gigas and Astragalus membranaceus ) in men with lower urinary tract symptoms: A randomized, double-blind, placebo-controlled clinical trial. Investigative and Clinical Urology. https://doi.org/10.4111/icu.20250025

Vancouver

Lee JH, Yoon D, Park GD, Kim KS, Kim SR, Shin WC, et al. SHPro ® (mixture of Angelica gigas and Astragalus membranaceus ) in men with lower urinary tract symptoms: A randomized, double-blind, placebo-controlled clinical trial. Investigative and Clinical Urology. 2025. doi:10.4111/icu.20250025

BibTeX
@article{Lee2025,
  author = {Lee, Ji Hun and Yoon, Dahye and Park, Geum Duck and Kim, Kyung Seok and Kim, Soo Ro and Shin, Woo Cheol and Lee, Seung Hwan and Lee, Dae Young},
  title = {SHPro ® (mixture of Angelica gigas and Astragalus membranaceus ) in men with lower urinary tract symptoms: A randomized, double-blind, placebo-controlled clinical trial},
  journal = {Investigative and Clinical Urology},
  year = {2025},
  doi = {10.4111/icu.20250025}
}
Kostenlos starten →